Health Condition 1: null- Diffuse Large B-Cell Lymphoma
Conditions
Interventions
Intervention1: nil: nil
Control Intervention1: nil: nil
Sponsors
Rajiv Gandhi Cancer Institute and Research Centre Sector Rohini New Delh
Eligibility
Inclusion criteria
Inclusion criteria: II. Patients diagnosed with denovo DLBCL at Rajiv Gandhi Cancer Institute and Research Centre within January 01, 2014 to December 31st, 2016. III. Patients will be followed up at Rajiv Gandhi Cancer Institute and Research Centre till May 31st, 2018.
Exclusion criteria
Exclusion criteria: I. Patients who didnâ??t complete the planned first line therapy. II. Patients with secondary malignancy. III. Patients with transformed lymphoma. IV. Patients infected with HIV. V. Patients infected with Hepatitis B or Hepatitis C virus. VI. Patients with active infection of fungi, bacterial and viral at the time of diagnosis of lymphoma. VII. Patients with autoimmune disorders (except Hashimotoâ??s Thyroiditis.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the association of ALC/AMC ratio with remission status in DLBCL. To determine the association of ALC/AMC with survival (Overall survival, Progression Free Survival) in DLBCL. Timepoint: Outcomes will be analysed on completion of 5 years. | — |
Secondary
| Measure | Time frame |
|---|---|
| i. To determine various factors (Age, Gender, Comorbidities, LDH, extranodal sites, no of extranodal sites, presence of B-symptoms, involvement of Bone Marrow, presence of bulky disease, IPI risk classification, staging, interim response, final response, relapse) predicting disease outcome and survival.Timepoint: Outcomes will be analysed on completion of 5 years. | — |
Countries
India
Contacts
Public ContactShifa Siddiqui
Rajiv Gandhi Cancer Institute and Research Centre
Outcome results
None listed